Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GYS1 | P13807 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.54 |
| ▸ | FASN | P49327 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750558 | 1.00 | CA2 (0.64) | CA2ALDH1A1L3MBTL1TDP1GYS1 | |
| SCHEMBL5035705 | 0.95 | TDP1 (0.64) | CA2ALDH1A1L3MBTL1TDP1GYS1 | |
| SCHEMBL5035699 | 0.95 | TDP1 (0.64) | CA2ALDH1A1L3MBTL1TDP1GYS1 | |
| SCHEMBL5702038 | 0.91 | HPGD (0.54) | CA2ALDH1A1L3MBTL1TDP1HPGD | |
| SCHEMBL5702058 | 0.91 | HPGD (0.54) | CA2ALDH1A1L3MBTL1TDP1HPGD | |
| SCHEMBL13229 | 0.91 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL13230 | 0.91 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL28789388 | 0.91 | CA2 (0.67) | CA2ALDH1A1L3MBTL1TDP1NPSR1 | |
| SCHEMBL5537767 | 0.91 | CA2 (0.75) | CA2ALDH1A1L3MBTL1TDP1HPGD | |
| SCHEMBL6787910 | 0.91 | CA2 (0.75) | CA2ALDH1A1L3MBTL1TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | claimed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | claimed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | claimed |
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | CA2 4495/4885ALDH1A1 1684/4885L3MBTL1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.